Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities: 2023

  • CG Oncology's Preferred Stock Liabilities was N/A to $120.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $120.0 million, marking a year-over-year change of. This contributed to the annual value of $120.0 million for FY2023, which is N/A change from last year.
  • Per CG Oncology's latest filing, its Preferred Stock Liabilities stood at $120.0 million for Q4 2023.
  • Over the past 5 years, CG Oncology's Preferred Stock Liabilities peaked at $120.0 million during Q4 2023, and registered a low of $120.0 million during Q4 2023.
  • Its 1-year average for Preferred Stock Liabilities is $120.0 million, with a median of $120.0 million in 2023.